Burkus et al. (2002) reported that treatment of patients with degenerative lumbar disc diseases with recombinant human BMP-2 gave higher interbody fusion rates (95%) than in a control group that received autogenous iliac crest bone graft (89%). Another randomized human clinical study showed that a BMP-2-treated group showed a higher fusion rate (88%) than a control iliac crest bone graft group (73%) in posterolateral fusions (Dimar et al. 2006). In addition, similar results have also been reported regarding the use of BMP-7 in treating posteolateral lumbar arthrodesis (Vaccaro et al. 2008). Here, BMP2 is linked to lumbar disk degenerative disorder.